Codes / ICD10CM / M31.10

M31.10 Thrombotic microangiopathy, unspecified

ICD10CM code

ICD10CM

Chat with GenHealth to automate any coding or chart task.

Name of the Condition

  • Thrombotic microangiopathy, unspecified

Summary

Thrombotic microangiopathy is a condition characterized by the formation of blood clots in small blood vessels, leading to reduced blood flow and potential organ damage. It involves the destruction of red blood cells and can affect multiple systems, including the kidneys, brain, and heart.

Causes

Thrombotic microangiopathy is caused by abnormalities in the blood vessel lining or clotting mechanisms, often triggered by immune-mediated processes, infections, or genetic factors. The exact cause may vary, but it typically involves endothelial cell injury and platelet activation.

Risk Factors

  • Autoimmune disorders (e.g., systemic lupus erythematosus).
  • Infections (e.g., Shiga toxin-producing E. coli, HIV).
  • Medications (e.g., certain chemotherapeutics, immunosuppressants).
  • Pregnancy or postpartum period.
  • Genetic predisposition (e.g., complement pathway deficiencies).

Symptoms

  • Fatigue and weakness.
  • Jaundice or pallor.
  • Swelling (edema) or high blood pressure.
  • Neurological symptoms (e.g., confusion, seizures).
  • Reduced urine output or kidney dysfunction.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, blood tests to assess hemolysis (e.g., low platelets, elevated LDH), and kidney function tests. Imaging or biopsy may be used to confirm organ involvement, and exclusion of other causes is essential.

Treatment Options

  • Plasma exchange (plasmapheresis) to remove harmful factors.
  • Corticosteroids to reduce inflammation.
  • Blood pressure management and supportive care.
  • Specific therapies for underlying causes (e.g., discontinuing triggering medications).

Prognosis and Follow-Up

Prognosis depends on the underlying cause and severity of organ involvement. Early treatment improves outcomes, but some cases may progress to chronic kidney disease or require long-term monitoring. Regular follow-up with blood tests and organ function assessments is recommended.

Complications

  • Acute kidney failure.
  • Stroke or neurological damage.
  • Heart failure or myocardial infarction.
  • Chronic anemia or thrombocytopenia.

Lifestyle & Prevention

  • Avoid known triggers (e.g., certain medications).
  • Maintain hydration and manage blood pressure.
  • Seek prompt treatment for infections.
  • Follow up with healthcare providers for underlying conditions.

When to Seek Professional Help

Seek immediate medical attention for symptoms like severe fatigue, confusion, chest pain, or reduced urine output, as these may indicate acute organ involvement.

Tips for Medical Coders

Document the clinical context, including organ involvement (e.g., renal, neurological) and any identified triggers or underlying conditions, to support accurate coding. Ensure documentation aligns with the unspecified nature of the code, avoiding assumptions about specific etiologies unless confirmed.

Medical Policies and Guidelines

Related policies from health plans

Cablivi (caplacizumab-yhdp )
Therapeutic Apheresis
Therapeutic Apheresis
Therapeutic Apheresis
Book a walkthrough

M31.10 policy automation walkthrough

Walk through the policies, prior authorization requirements, and workflow automation opportunities connected to this code.